Skip to main content
. Author manuscript; available in PMC: 2018 Aug 7.
Published in final edited form as: Int J Pharm. 2017 Jun 13;528(1-2):463–470. doi: 10.1016/j.ijpharm.2017.06.031

Fig. 9.

Fig. 9

In-vitro anticancer activity of gemcitabine-lipid conjugates nanoemulsions against pancreatic cancer cell lines; (A) Bx-PC-3 and (B) PANC-1. Cells were treated for 72 hr. Values reported are the mean ± SD for triplicate samples. * P value < 0.05: indicates that gemcitabine-lipid conjugates nanoemulsions had significantly higher anticancer activity than the gemcitabine-lipid conjugates in DMSO against both cell lines. ** P value < 0.05: indicates that the Gem-γ-T3 conjugate in DMSO had significantly higher anticancer activity than the other Gem-lipid conjugates in DMSO against both cell lines